# A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).

> **NCT00038961** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1309 (actual)

## Conditions studied

- Thromboembolism

## Interventions

- **DRUG:** fondaparinux sodium
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00038961
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2004-10
- **Final completion:** 2004-10
- **Target enrollment:** 1309 (ACTUAL)
- **Last updated:** 2016-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038961, "A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00038961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*